Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • efimosfermin alfa
Monthly Efimosfermin Alfa Demonstrates Safety and Tolerability in MASH-Related Fibrosis: Insights from a Phase 2 Trial
Posted inGastroenterology Internal Medicine news

Monthly Efimosfermin Alfa Demonstrates Safety and Tolerability in MASH-Related Fibrosis: Insights from a Phase 2 Trial

Posted by MedXY By MedXY 02/16/2026
The Phase 2 trial of efimosfermin alfa (BOS-580) shows that once-monthly dosing is safe and well-tolerated in patients with MASH and F2/F3 fibrosis, supporting its continued clinical development as a potential liver-targeted therapy.
Read More
Efimosfermin Alfa (BOS-580) in Metabolic Dysfunction-Associated Steatohepatitis: Promising Phase 2a Results
Posted inClinical Updates Gastroenterology Internal Medicine news Specialties

Efimosfermin Alfa (BOS-580) in Metabolic Dysfunction-Associated Steatohepatitis: Promising Phase 2a Results

Posted by MedXY By MedXY 08/02/2025
Efimosfermin alfa, a long-acting FGF21 analogue, demonstrated a favorable safety profile and significant reductions in hepatic fat in patients with metabolic dysfunction-associated steatohepatitis (MASH) in a phase 2a randomized controlled trial.
Read More
  • Evolution and Future Frontiers of PCSK9 Inhibition: From Genetic Discovery to Genomic Medicine
  • Navigating the AfMR Maze: Expert Consensus and the Future of Mitral Regurgitation Diagnosis
  • Breaking the Brake: How Annexin A2 Inhibition Restores Mitophagy and Salvages the Infarcted Heart
  • Every Hour Counts: Emergency Department Boarding Linked to Increased Clinical Deterioration and Mortality
  • Beyond Shared Identity: How Physician-Patient Racial Concordance Modulates Inpatient Advance Care Planning
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality nutrition obesity older adults oncology Pediatrics Physical Activity precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in